Advertisement
News
Advertisement

Ischemix boosted by positive trial data

Fri, 06/17/2011 - 10:34am
Mass High Tech: The Journal of New England Technology

Ischemix LLC, a biotechnology firm in Maynard, has returned positive data on its drug candidate to prevent peri-operative cardiac ischemia-reperfusion injury, a temporary decrease in sufficient blood flow, in patients following percutaneous coronary intervention (PCI) procedures that are meant to treat those symptoms.

Based on the data from the Phase 2a clinical trial, Ischemix’s treatment, called CMX-2043, was found to be safe at all doses and also landed certain endpoints in measuring cardiac health.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading